Gene therapy for restoring heart rhythm.

Area of Science:

• Biotechnology
• Cardiovascular Research
• Gene Therapy

Background:

• Gene therapy for biological pacemakers has been explored for 15 years, primarily focusing on the HCN gene family.
• The HCN gene family encodes the cardiac pacemaker current (If), crucial for heart rate regulation and autonomic responsiveness.
• Previous attempts using native or mutated HCN channels alone failed to achieve adequate heart rates in large animal models.

Purpose of the Study:

• To evaluate the efficacy of dual gene therapy approaches for biological pacemakers.
• To overcome limitations of single-gene therapies in achieving physiological heart rates.
• To explore strategies for enhancing biological pacemaker function through combined gene expression.

Main Methods:

• Investigated dual gene therapy combining HCN variants with other genes.
• Targeted genes to reduce outward current, increase inward current, or enhance cAMP synthesis.
• Assessed basal and maximal heart rates in large animal models.

Main Results:

• Dual gene therapy approaches demonstrated appropriate basal and maximal heart rates.
• These approaches showed reduced reliance on electronic pacemakers during the study period.
• Successful modulation of cardiac currents and cAMP pathways was achieved.

Conclusions:

• Dual gene therapy represents a promising strategy for developing effective biological pacemakers.
• Further research is needed on gene combinations, safety, and viral vector persistence.
• This approach offers potential for a biological alternative or adjunct to electronic pacemakers.